CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens.
Methods Mol Biol
; 2410: 209-228, 2022.
Article
in English
| MEDLINE | ID: covidwho-1576030
ABSTRACT
The COVID-19 pandemic brought to the fore the urgent need for vaccine design and delivery platforms that can be rapidly deployed for manufacture and distribution. Though the mRNA and adenoviral vector platforms have been enormously successful to control SARS-CoV-2 viral infections, it is unclear if this could be replicated against more complex pathogens or the emerging variants. Recently, we described a "universal" platform that can incorporate multiple vaccine targets into the same nanoparticle scaffold by CRISPR engineering of bacteriophage T4. A T4-COVID vaccine designed with this technology elicited broad immunogenicity and complete protection against virus challenge in a mouse model. Here, we describe the detailed methodology to generate recombinant bacteriophage T4 backbones using CRISPR that can also be broadly applicable to other bacteriophages that abundantly pervade the Earth.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Bacteriophage T4
/
Clustered Regularly Interspaced Short Palindromic Repeats
/
COVID-19 Vaccines
/
COVID-19
Topics:
Vaccines
/
Variants
Limits:
Animals
/
Humans
Language:
English
Journal:
Methods Mol Biol
Journal subject:
Molecular Biology
Year:
2022
Document Type:
Article
Affiliation country:
978-1-0716-1884-4_10
Similar
MEDLINE
...
LILACS
LIS